Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

702
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
702
Dementia01:30

Dementia

458
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
458

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying motor-cognitive reserve using a novel multi-modal stress test.

Brain communications·2025
Same author

Anti-amyloid treatments for Alzheimer's disease: A study on physicians' perspectives.

Journal of Alzheimer's disease : JAD·2024
Same author

Discussion on "Optimal test procedures for multiple hypotheses controlling the familywise expected loss" by Willi Maurer, Frank Bretz, and Xiaolei Xun.

Biometrics·2023
Same author

A novel performance scoring quantification framework for stress test set-ups.

PloS one·2023
Same author

Does the delivery mode affect post-birth neonatal serum C-reactive protein levels? A causal effect analysis.

Journal of paediatrics and child health·2022
Same author

Prognostic value of neutrophil-to-lymphocyte ratio in COVID-19 compared with Influenza and respiratory syncytial virus infection.

Scientific reports·2021

Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.6K

Novel Alzheimer's disease subtypes identified using a data and knowledge driven strategy.

Alexis Mitelpunkt1,2,3, Tal Galili4, Tal Kozlovski4

  • 1Department of Statistics and Operations Research, Tel Aviv University, Tel Aviv, Israel. alexism@tauex.tau.ac.il.

Scientific Reports
|January 30, 2020
PubMed
Summary

This study identified six new Alzheimer's disease (AD) subtypes using big data analysis. These subtypes offer more homogeneous patient groups for improved clinical trials and Alzheimer's disease research.

More Related Videos

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
04:41

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

19.2K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.3K

Related Experiment Videos

Last Updated: Dec 29, 2025

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.6K
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
04:41

Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration

Published on: January 9, 2020

19.2K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.3K

Area of Science:

  • Neuroscience
  • Medical Informatics
  • Biostatistics

Background:

  • Alzheimer's disease (AD) patient populations exhibit significant heterogeneity.
  • Current AD diagnostic subgroups limit data analytics for clinical trials and care improvements.

Purpose of the Study:

  • To define clinically homogeneous AD patient groups.
  • To link clinical characteristics with biological markers for refined AD classification.

Main Methods:

  • Employed a "3C strategy" integrating medical knowledge into big data analysis.
  • Analyzed a large dataset from the Alzheimer's Neuroimaging Initiative (ADNI).

Main Results:

  • Identified 6 novel AD subtypes distinct from current diagnostic categories.
  • These subtypes show different patterns in clinical measures and potential biomarkers.
  • Specific subtypes like "Anosognosia dementia" and "Uncompensated mild cognitive impairment (MCI)" were differentiated.

Conclusions:

  • Data-driven analysis revealed sub-phenotypic clinical clusters beyond current AD diagnoses.
  • These homogeneous subgroups are associated with biomarkers and can advance brain medicine research.
  • The identified subtypes provide a foundation for enhanced clinical trial design and personalized AD care.